Microlin Bio (OTC: MICBE) is an emerging therapeutics company focused on microRNA and its role in oncology. MicroRNAs are recently discovered, naturally occurring RNA molecules that do not encode proteins, but instead regulate gene expression and various biological pathways. Improper balance of microRNAs is believed to be linked to many diseases, including cancer. The company has agreements to exclusively license a portfolio of approximately 100 issued and pending patents and patent applications covering numerous microRNAs and a novel delivery technology for potential use in the development of its therapeutic product candidates. For more information, visit the company’s website at www.microlinbio.com